Article
Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
BMC cancer - 21 Sept 2011
Yeh Chau-Ting, Chen Tiffany, Hsu Chao-Wei, Chen Yi-Cheng, Lai Ming-Wei, Liang Kung-Hao, Chen Tse-Ching
Abstract excerpt
BACKGROUND: Development of the hepatitis B virus (HBV) rtA181T/sW172* mutant could occur during prolonged lamivudine (LAM) therapy, conferring cross resistance to adefovir. Recent studies demonstrated an increased oncogenic potential of this mutant in NIH3T3 cells. In this study, we aimed to investigate the clinical significance of this finding. METHODS: Serum samples from 123 LAM-resistant chronic hepatitis B...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
